VC  Prospect Venture Partners

     Office Locations:

435 Tasso Street, Suite 200
Palo Alto, CA 94301
Phone: 650-327-8800
Fax: 650-324-8838



  • Early
  • Expansion
  • Growth
  • Seed



  • Life Sciences & Healthcare



    With $1 billion of capital under management, Prospect Venture Partners invests in biomedical technology and life science companies. Prospect seeks to ultimately invest $10-20 million in each company in its portfolio, typically as a lead investor or as a co-lead in an investor syndicate. The firm invests in companies with a broad range of development and financing requirements including: incubating new companies, investing in first and second venture financing rounds, and participating in later stage private and public companies (with proven business models requiring expansion capital). First round investments most often range from $500,000 to $10 million.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    David Schnell M.D. Managing Director
    Don Hayden Senior Advisor
    Rebecca Lucia CFA CFO
    Russell Hirsch M.D., Ph.D. Managing Director


    Portfolio companies include:

        web link

        web link

      Azelon Pharmaceuticals
        web link

        web link

      Cabochon Aesthetics
        web link

        web link

        web link

      Hansen Medical
        web link

      Kythera Biopharmaceuticals
        web link

      Lux Biosciences
        web link

        web link

        web link

      NGM Biopharmaceuticals
        web link

      NinePoint Medical
        web link

      Nora Therapeutics
        web link

        web link

        web link

      Opus Medical
        web link

        web link

      Pathwork Diagnostics
        web link

      Patient Care
        web link

      PCI Holding Corp.
        web link

      Portola Pharmaceuticals
        web link

        web link

        web link

        web link


    Recent News: